Assessment of symptoms and signs of benign prostatic hyperplasia using the International Prostate Symptom Score in clinical practice
1 Department of Family Medicine, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
2 Centre of Family Medicine, Public Institution Health Centre of Zenica, Zenica, Bosnia and Herzegovina.
3 Malteser Waldkrankenhaus St. Marien Erlangen, Erlangen, Germany.
4 Department of Social Medicine, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
5 Department of Neurology, General Hospital “Prim. Dr. Abdulah Nakas” Sarajevo, Sarajevo, Bosnia and Herzegovina.
6 Polyclinic for Laboratory Diagnostics, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina,
7 Urology Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
8 Bosnalijek d.d., Sarajevo, Bosnia and Herzegovina.
Research Article
World Journal of Advanced Research and Reviews, 2024, 21(03), 2421–2428
Publication history:
Received on 14 February 2024; revised on 25 March 2024; accepted on 27 March 2024
Abstract:
Introduction: Benign prostatic hyperplasia (BHP) is one of the most common, progressive diseases in elderly men. It is very important to diagnose this disease in its early stages. The international prostate symptom score (IPSS) is a very helpful tool to be used for this purpose.
Aims: The main goal of this study was to analyze the signs and symptoms of benign prostatic hyperplasia and its impact on a patient's quality of life.
Patients and Methods: This descriptive randomized study included 112 male examinees aged 50-70 years. We used IPSS as a survey tool.
Results: The average age of the examinees was 61.02 (± 6,18). 56.3% of examinees had mild symptoms, 31.3% had moderate symptoms and 12.5% of our examinees had severe lower urinary tract symptoms. Nocturia was the most common symptom. Irritative symptoms were present in 76.8% of examinees compared to obstructive symptoms which occurred in 8.9%, and 14.3% had both types of symptoms. Hypertension was the most common comorbidity (in 50.9% of cases). The majority of examinees answered that they would be satisfied with their quality of life if their symptoms do not change in the future.
Conclusions: Assessment of symptoms and signs of benign prostatic hyperplasia using IPSS in clinical practice has proven to be useful in the timely approach of clinical physicians.
Keywords:
Benign prostatic hyperplasia; IPSS-International prostate symptom score; Quality of life
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0